NASDAQ:RKDA Arcadia Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arcadia Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.82 +0.07 (+2.55 %) (As of 09/29/2020 12:00 AM ET) Add Compare Share Today's Range$2.75Now: $2.82▼$2.9550-Day Range$2.54MA: $3.12▼$3.8752-Week Range$2.30Now: $2.82▼$6.63Volume146,614 shsAverage Volume228,667 shsMarket Capitalization$30.17 millionP/E RatioN/ADividend YieldN/ABeta-0.58 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Arcadia Biosciences, Inc., an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products. In addition, the company has various programs under development comprising fiber resistant starch wheat, whole grain flour, and reduced gluten wheat programs. Arcadia Biosciences, Inc. has strategic collaborations with Dow AgroSciences and Ardent Mills LLC to develop and commercialize wheat varieties. The company was founded in 2002 and is headquartered in Davis, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingArcadia Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, Arcadia Biosciences has a forecasted upside of 396.5% from its current price of $2.82.Amount of Analyst CoverageArcadia Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesArcadia Biosciences has received 272 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArcadia Biosciences has received 252 “underperform” votes. (Add your “underperform” vote.)Community SentimentArcadia Biosciences has received 51.91% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arcadia Biosciences and other stocks. Vote “Outperform” if you believe RKDA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RKDA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.50% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by InstitutionsOnly 4.89% of the stock of Arcadia Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcadia Biosciences are expected to grow in the coming year, from ($2.25) to ($1.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 2.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Agricultural production - crops Sub-IndustryN/A SectorBasic Materials Current SymbolNASDAQ:RKDA Previous Symbol CUSIPN/A CIK1469443 Webwww.arcadiabio.com Phone530-756-7077Debt Debt-to-Equity Ratio0.20 Current Ratio3.12 Quick Ratio2.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.17 million Price / Sales25.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.96 per share Price / Book2.94Profitability EPS (Most Recent Fiscal Year)($3.37) Net Income$-28,810,000.00 Net Margins-1,973.82% Return on Equity-175.11% Return on Assets-60.58%Miscellaneous Employees44 Outstanding Shares10,700,000Market Cap$30.17 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $2.82 +0.07 (+2.55 %) (As of 09/29/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive RKDA News and Ratings via Email Sign-up to receive the latest news and ratings for RKDA and its competitors with MarketBeat's FREE daily newsletter. Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions How has Arcadia Biosciences' stock price been impacted by Coronavirus (COVID-19)? Arcadia Biosciences' stock was trading at $3.17 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RKDA stock has decreased by 11.0% and is now trading at $2.82. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Arcadia Biosciences? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcadia Biosciences. When is Arcadia Biosciences' next earnings date? Arcadia Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Arcadia Biosciences. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences Inc (NASDAQ:RKDA) announced its quarterly earnings results on Thursday, August, 13th. The basic materials company reported ($0.71) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.61) by $0.10. The basic materials company earned $0.28 million during the quarter, compared to analysts' expectations of $1.54 million. Arcadia Biosciences had a negative net margin of 1,973.82% and a negative return on equity of 175.11%. View Arcadia Biosciences' earnings history. When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work? Arcadia Biosciences shares reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split. What price target have analysts set for RKDA? 2 analysts have issued twelve-month target prices for Arcadia Biosciences' stock. Their forecasts range from $12.00 to $16.00. On average, they expect Arcadia Biosciences' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 396.5% from the stock's current price. View analysts' price targets for Arcadia Biosciences. Are investors shorting Arcadia Biosciences? Arcadia Biosciences saw a increase in short interest in August. As of August 31st, there was short interest totaling 483,900 shares, an increase of 10.0% from the August 15th total of 439,800 shares. Based on an average daily trading volume, of 209,200 shares, the short-interest ratio is currently 2.3 days. View Arcadia Biosciences' Short Interest. Who are some of Arcadia Biosciences' key competitors? Some companies that are related to Arcadia Biosciences include AMAYA Global (AYAG), S&W Seed (SANW), China Liaoning Dingxu Ecological Agriculture Development (CLAD), Origin Agritech (SEED), Royal Hawaiian Orchards (NNUTU), Margo Caribe (MRGO), Two Rivers Water and Farming (TURV), Shineco (TYHT), Yew Bio-Pharm Group (YEWB) and YaSheng Group (HERB). View all competitors. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include BioNano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania R.E.I.T. (PEI), Novan (NOVN), Cannabics Pharmaceuticals (CNBX) and Enerplus (ERF). Who are Arcadia Biosciences' key executives? Arcadia Biosciences' management team includes the following people: Mr. Rajendra Ketkar, Pres, CEO & Director (Age 65)Mr. Matthew T. Plavan, CFO, Sec. & Pres of Arcadia Specialty Genomics (Age 55)Ms. Sarah Reiter, Chief Commercial Officer (Age 47)Dr. Randy Shultz Ph.D., Head of R&DDr. Zhongjin Lu Ph.D., Director of Product Devel. (Age 53) When did Arcadia Biosciences IPO? (RKDA) raised $66 million in an initial public offering (IPO) on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO. What is Arcadia Biosciences' stock symbol? Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA." How do I buy shares of Arcadia Biosciences? Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arcadia Biosciences' stock price today? One share of RKDA stock can currently be purchased for approximately $2.82. How big of a company is Arcadia Biosciences? Arcadia Biosciences has a market capitalization of $30.17 million and generates $1.17 million in revenue each year. The basic materials company earns $-28,810,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis. Arcadia Biosciences employs 44 workers across the globe. What is Arcadia Biosciences' official website? The official website for Arcadia Biosciences is www.arcadiabio.com. How can I contact Arcadia Biosciences? Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected] This page was last updated on 9/30/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
